

# KUROS BIOSCIENCES AG

ISIN: CH0325814116 WKN: 32581411 Asset Class: **Stock**

<b>Company</b>	2024/06/28 09:15:10
<b>Price</b>	<b>11.52</b> CHF
<b>Difference</b>	↑0.70%(0.08)



<b>Contact Details</b>	
KUROS BIOSCIENCES LTD.	Tel: +41-44-733-47-47
--	Fax: +41-44-733-47-40
Wagistrasse 25	Web: <a href="http://www.kurosbiosciences.com">http://www.kurosbiosciences.com</a>
8952 Schlieren	E-mail: <a href="mailto:info@kuros.ch">info@kuros.ch</a>

## Company Profile

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	27,194,000		31,393,000		32,892,000	
<b>Common stock capital</b>		3,678,000		3,656,000		3,281,000
<b>Fixed assets</b>	48,712,000		56,626,000		63,424,000	
<b>Equity capital of a company</b>		56,712,000		68,860,000		76,976,000
<b>Cash and cash equivalents</b>	14,208,000		24,065,000		28,623,000	
<b>Accrued liabilities</b>		0		0		353,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		13,187,000		12,589,000		11,288,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		6,007,000		6,570,000		8,052,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		0
<b>Total assets</b>	75,906,000	75,906,000	88,019,000	88,019,000	96,316,000	96,316,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	5	6	6
<b>Equity ratio</b>	74.71%	78.23%	79.92%
<b>Debt-equity ratio</b>	33.84%	27.82%	25.12%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	-2.85%	8.73%	21.07%

# KUROS BIOSCIENCES AG

ISIN: CH0325814116 WKN: 32581411 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	33,564,000	17,986,000	13,815,000
<b>Net income</b>	-13,727,000	-14,595,000	-7,541,000
<b>EBIT</b>	-13,726,923	-14,024,178	-9,143,981
<b>Operating income before taxes</b>	-13,347,000	-15,991,000	-9,554,000
<b>Cash Flow</b>	-8,844,000	-7,348,000	-5,453,000
<b>Net interest income</b>	-186,000	-2,545,000	-787,000
<b>Research and development expenses</b>	5,599,000	5,194,000	4,989,000
<b>Income taxes</b>	380,000	-1,396,000	-2,013,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	7,001,450	3,126,566	2,401,508

## Board of Directors

Joost de Bruijn	Member of the administrative board
Albert Arp	Member of the administrative board
Oliver Walker	Member of the administrative board
Clemens van Blitterswijk	Chairman of the administrative board

## Members of Management Board

Chris Fair	Chairman of Managing Board
Philippe Saudan	Member of Executive Committee
Joost de Bruijn	Member of Executive Committee
Daniel Geiger	Member of Executive Committee
John Griffin	Member of Executive Committee
Sjoerd Musters	Member of Executive Committee